RhumbLine Advisers’s Neurogene NGNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $229K | Sell |
15,325
-368
| -2% | -$5.5K | ﹤0.01% | 3152 |
|
|
2025
Q1 | $184K | Sell |
15,693
-11
| -0.1% | -$129 | ﹤0.01% | 3143 |
|
|
2024
Q4 | $359K | Buy |
15,704
+1,326
| +9% | +$30.3K | ﹤0.01% | 2880 |
|
|
2024
Q3 | $603K | Buy |
14,378
+889
| +7% | +$37.3K | ﹤0.01% | 2577 |
|
|
2024
Q2 | $491K | Buy |
+13,489
| New | +$491K | ﹤0.01% | 2694 |
|
|
2022
Q2 | – | Sell |
-2,073
| Closed | -$78K | – | 3189 |
|
|
2022
Q1 | $78K | Sell |
2,073
-164
| -7% | -$6.17K | ﹤0.01% | 2934 |
|
|
2021
Q4 | $216K | Sell |
2,237
-30
| -1% | -$2.9K | ﹤0.01% | 2817 |
|
|
2021
Q3 | $328K | Sell |
2,267
-256
| -10% | -$37K | ﹤0.01% | 2735 |
|
|
2021
Q2 | $466K | Buy |
2,523
+763
| +43% | +$141K | ﹤0.01% | 2595 |
|
|
2021
Q1 | $433K | Sell |
1,760
-114
| -6% | -$28K | ﹤0.01% | 2557 |
|
|
2020
Q4 | $529K | Buy |
1,874
+172
| +10% | +$48.6K | ﹤0.01% | 2422 |
|
|
2020
Q3 | $409K | Sell |
1,702
-90
| -5% | -$21.6K | ﹤0.01% | 2380 |
|
|
2020
Q2 | $595K | Buy |
+1,792
| New | +$595K | ﹤0.01% | 2266 |
|